Philip Hampton, non-executive chairman of GlaxoSmithKline Plc since May 2015, has decided to step down from the position, triggering the start of recruitment for a successor, GSK announced on 21 January 2019.
Mr Hampton’s departure comes nearly two years after the appointment of Emma Walmsley as chief executive, and the recently announced restructuring that will see GSK spin out an enlarged consumer healthcare business into a separately listed company. This restructuring is expected to take place over the next three years.